KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZN) Return on Sales (2016 - 2025)

Historic Return on Sales for Astrazeneca (AZN) over the last 17 years, with Q4 2025 value amounting to 0.17%.

  • Astrazeneca's Return on Sales rose 600.0% to 0.17% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.21%, marking a year-over-year increase of 500.0%. This contributed to the annual value of 0.21% for FY2025, which is 500.0% up from last year.
  • Latest data reveals that Astrazeneca reported Return on Sales of 0.17% as of Q4 2025, which was up 600.0% from 0.21% recorded in Q3 2025.
  • Astrazeneca's 5-year Return on Sales high stood at 5.18% for Q3 2022, and its period low was 0.2% during Q3 2021.
  • Over the past 5 years, Astrazeneca's median Return on Sales value was 0.18% (recorded in 2023), while the average stood at 0.72%.
  • In the last 5 years, Astrazeneca's Return on Sales soared by 53800bps in 2022 and then crashed by -50400bps in 2023.
  • Quarter analysis of 5 years shows Astrazeneca's Return on Sales stood at 0.05% in 2021, then surged by 9399bps to 4.92% in 2022, then tumbled by -98bps to 0.07% in 2023, then soared by 50bps to 0.11% in 2024, then skyrocketed by 52bps to 0.17% in 2025.
  • Its Return on Sales stands at 0.17% for Q4 2025, versus 0.21% for Q3 2025 and 0.22% for Q2 2025.